Evidence map›Paper›PMID 38751935›Full record

ArticleNAR cancer2024

Neural-net-based cell deconvolution from DNA methylation reveals tumor microenvironment associated with cancer prognosis.

Yoshiaki Yasumizu, Masaki Hagiwara, Yuto Umezu, Hiroaki Fuji, Keiko Iwaisako, Masataka Asagiri, Shinji Uemoto, Yamami Nakamura, Sophia Thul, Azumi Ueyama and 12 more

Abstract read
In one paragraph

Article in NAR cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yoshiaki YasumizuDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.ORCID https://orcid.org/0000-0002-9872-4909
Masaki HagiwaraDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.ORCID https://orcid.org/0000-0002-7146-2160
Yuto UmezuFaculty of Medicine, Osaka University, Suita, Osaka, Japan.
Hiroaki FujiDepartment of Hepato-Biliary-Pancreatic Surgery, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
Keiko IwaisakoDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.
Masataka AsagiriDepartment of Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
Shinji UemotoShiga University Medical Science, Otsu, Shiga, Japan.
Yamami NakamuraDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Sophia ThulDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.
Azumi UeyamaPharmaceutical Research Division, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.
Kazunori YokoiDepartment of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Atsushi TanemuraDepartment of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Yohei NoseDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Takuro SaitoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Hisashi WadaDepartment of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Mamoru KakudaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Masaharu KoharaDepartment of Pathology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Satoshi NojimaDepartment of Pathology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Eiichi MoriiDepartment of Pathology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Shimon SakaguchiDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.ORCID https://orcid.org/0000-0001-8265-6094
Naganari OhkuraDepartment of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA methylation is a pivotal epigenetic modification that defines cellular identity. While cell deconvolution utilizing this information is considered useful for clinical practice, current methods for deconvolution are limited in their accuracy and resolution. In this study, we collected DNA methylation data from 945 human samples derived from various tissues and tumor-infiltrating immune cells and trained a neural network model with them. The model, termed MEnet, predicted abundance of cell population together with the detailed immune cell status from bulk DNA methylation data, and showed consistency to those of flow cytometry and histochemistry. MEnet was superior to the existing methods in the accuracy, speed, and detectable cell diversity, and could be applicable for peripheral blood, tumors, cell-free DNA, and formalin-fixed paraffin-embedded sections. Furthermore, by applying MEnet to 72 intrahepatic cholangiocarcinoma samples, we identified immune cell profiles associated with cancer prognosis. We believe that cell deconvolution by MEnet has the potential for use in clinical settings.

Identifiers

PMID38751935
PMCPMC11094754

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.